The global in-vivo toxicology market is experiencing remarkable growth as pharmaceutical, biotechnology, and research organizations increasingly prioritize comprehensive safety testing during drug development. In-vivo toxicology studies play a critical role in evaluating the safety, efficacy, and biological effects of new drugs, chemicals, and medical products before they advance to human clinical trials. Growing investments in pharmaceutical research, stricter regulatory requirements, and increasing demand for innovative therapies are driving the expansion of this market.
According to Fortune Business Insights, the global in-vivo toxicology market was valued at USD 39.27 billion in 2025 and is projected to grow from USD 44.18 billion in 2026 to USD 113.36 billion by 2034, registering a robust CAGR of 12.50% during the forecast period. As drug discovery pipelines expand worldwide, the demand for reliable preclinical testing solutions is expected to remain strong.
In-vivo toxicology refers to the study of how drugs, chemicals, biologics, and medical products affect living organisms. These studies help researchers evaluate toxicity, metabolism, pharmacokinetics, and potential side effects before new therapies are approved for human use.
The findings from in-vivo toxicology studies are essential for regulatory submissions and help pharmaceutical companies identify potential risks early in the development process. These studies contribute to safer medicines while reducing the likelihood of costly failures during clinical trials.
Global pharmaceutical companies continue to invest heavily in developing innovative medicines for cancer, neurological disorders, cardiovascular diseases, and rare diseases. Every new drug candidate requires extensive preclinical safety testing before entering human trials, significantly increasing the demand for in-vivo toxicology services.
Growing R&D investments by biotechnology firms are further supporting market expansion.
Regulatory agencies worldwide require comprehensive toxicology data before approving clinical studies or commercial drug launches. Organizations such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory bodies emphasize rigorous safety evaluations to protect patient health.
As regulations become more stringent, pharmaceutical companies increasingly rely on specialized toxicology service providers to ensure compliance.
The rapid development of biologics, cell therapies, gene therapies, vaccines, and personalized medicines has created new opportunities for in-vivo toxicology testing. These advanced therapies often require specialized safety assessments due to their complex biological characteristics.
The continued expansion of precision medicine is expected to further increase demand for advanced toxicology services.
Many pharmaceutical companies are outsourcing toxicology studies to Contract Research Organizations (CROs) to reduce operational costs, accelerate product development, and gain access to specialized expertise.
Outsourcing allows drug developers to improve efficiency while maintaining compliance with global regulatory standards.
Technological advancements are transforming the in-vivo toxicology landscape.